A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy Via Chronic Activation of Nonsense-Mediated Decay

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2018 Dec 28

PMID 30586709

Citations 76

Authors

Timon Seeger

Rajani Shrestha

Chi Keung Lam

Caressa Chen

Wesley L McKeithan

Edward Lau

Alexa Wnorowski

George McMullen

Matthew Greenhaw

Jaecheol Lee

Angelos Oikonomopoulos

Soah Lee

Huaxiao Yang

Mark Mercola

Matthew Wheeler

Euan A Ashley

Fan Yang

Ioannis Karakikes

Joseph C Wu

Affiliations

Soon will be listed here.

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 ( MYBPC3) resulting in a premature termination codon (PTC). The underlying mechanisms of how PTC mutations in MYBPC3 lead to the onset and progression of HCM are poorly understood. This study's aim was to investigate the molecular mechanisms underlying the pathogenesis of HCM associated with MYBPC3 PTC mutations by utilizing human isogenic induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs).

Methods: Isogenic iPSC lines were generated from HCM patients harboring MYBPC3 PTC mutations (p.R943x; p.R1073P_Fsx4) using genome editing. Comprehensive phenotypic and transcriptome analyses were performed in the iPSC-CMs.

Results: We observed aberrant calcium handling properties with prolonged decay kinetics and elevated diastolic calcium levels in the absence of structural abnormalities or contracile dysfunction in HCM iPSC-CMs as compared to isogenic controls. The mRNA expression levels of MYBPC3 were significantly reduced in mutant iPSC-CMs, but the protein levels were comparable among isogenic iPSC-CMs, suggesting that haploinsufficiency of MYBPC3 does not contribute to the pathogenesis of HCM in vitro. Furthermore, truncated MYBPC3 peptides were not detected. At the molecular level, the nonsense-mediated decay pathway was activated, and a set of genes involved in major cardiac signaling pathways was dysregulated in HCM iPSC-CMs, indicating an HCM gene signature in vitro. Specific inhibition of the nonsense-mediated decay pathway in mutant iPSC-CMs resulted in reversal of the molecular phenotype and normalization of calcium-handling abnormalities.

Conclusions: iPSC-CMs carrying MYBPC3 PTC mutations displayed aberrant calcium signaling and molecular dysregulations in the absence of significant haploinsufficiency of MYBPC3 protein. Here we provided the first evidence of the direct connection between the chronically activated nonsense-mediated decay pathway and HCM disease development.

Citing Articles

AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models.

Greer-Short A, Greenwood A, Leon E, Qureshi T, von Kraut K, Wong J Nat Commun. 2025; 16(1):2196.

PMID: 40038304 PMC: 11880196. DOI: 10.1038/s41467-025-57481-7.

CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity.

Liu C, Shen M, Liu Y, Manhas A, Zhao S, Zhang M Cell Stem Cell. 2024; 31(12):1760-1776.e9.

PMID: 39515331 PMC: 11646563. DOI: 10.1016/j.stem.2024.10.007.

Cardiomyopathy: pathogenesis and therapeutic interventions.

Huang S, Li J, Li Q, Wang Q, Zhou X, Chen J MedComm (2020). 2024; 5(11):e772.

PMID: 39465141 PMC: 11502724. DOI: 10.1002/mco2.772.

Patient-derived induced pluripotent stem cells to study non-canonical splicing variants associated with Hypertrophic Cardiomyopathy.

Jager J, Ribeiro M, Furtado M, Carvalho T, Syrris P, Lopes L Stem Cell Res. 2024; 81:103582.

PMID: 39447317 PMC: 11649531. DOI: 10.1016/j.scr.2024.103582.

CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation.

Dutton L, Dudhia J, Guest D, Connolly D PLoS One. 2024; 19(10):e0311761.

PMID: 39388496 PMC: 11466433. DOI: 10.1371/journal.pone.0311761.

References

Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg K . Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res. 2005; 66(1):33-44. DOI: 10.1016/j.cardiores.2005.01.004. View

Termglinchan V, Seeger T, Chen C, Wu J, Karakikes I . Efficient Genome Editing in Induced Pluripotent Stem Cells with Engineered Nucleases In Vitro. Methods Mol Biol. 2016; 1521:55-68. DOI: 10.1007/978-1-4939-6588-5_4. View

Carrier L, Knoll R, Vignier N, Keller D, Bausero P, Prudhon B . Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res. 2004; 63(2):293-304. DOI: 10.1016/j.cardiores.2004.04.009. View

Karam R, Lou C, Kroeger H, Huang L, Lin J, Wilkinson M . The unfolded protein response is shaped by the NMD pathway. EMBO Rep. 2015; 16(5):599-609. PMC: 4428047. DOI: 10.15252/embr.201439696. View

Birket M, Ribeiro M, Kosmidis G, Ward D, Leitoguinho A, van de Pol V . Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. Cell Rep. 2015; 13(4):733-745. PMC: 4644234. DOI: 10.1016/j.celrep.2015.09.025. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

van Dijk S, Dooijes D, Dos Remedios C, Michels M, Lamers J, Winegrad S . Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009; 119(11):1473-83. DOI: 10.1161/CIRCULATIONAHA.108.838672. View

Karakikes I, Ameen M, Termglinchan V, Wu J . Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res. 2015; 117(1):80-8. PMC: 4546707. DOI: 10.1161/CIRCRESAHA.117.305365. View

Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna W . Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res. 2009; 105(3):219-22. DOI: 10.1161/CIRCRESAHA.109.202440. View

10.

van Dijk S, Boontje N, Heymans M, Ten Cate F, Michels M, Dos Remedios C . Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations. Pflugers Arch. 2013; 466(8):1619-33. DOI: 10.1007/s00424-013-1391-0. View

11.

Ma N, Zhang J, Itzhaki I, Zhang S, Chen H, Haddad F . Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells. Circulation. 2018; 138(23):2666-2681. PMC: 6298866. DOI: 10.1161/CIRCULATIONAHA.117.032273. View

12.

Prondzynski M, Kramer E, Laufer S, Shibamiya A, Pless O, Flenner F . Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes. Mol Ther Nucleic Acids. 2017; 7:475-486. PMC: 5458066. DOI: 10.1016/j.omtn.2017.05.008. View

13.

Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Coirault C . Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res. 2007; 101(9):928-38. DOI: 10.1161/CIRCRESAHA.107.158774. View

14.

Garg P, Oikonomopoulos A, Chen H, Li Y, Lam C, Sallam K . Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. J Am Coll Cardiol. 2018; 72(1):62-75. PMC: 6050025. DOI: 10.1016/j.jacc.2018.04.041. View

15.

Maron B, Maron M, Semsarian C . Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012; 60(8):705-15. DOI: 10.1016/j.jacc.2012.02.068. View

16.

Breckwoldt K, Letuffe-Breniere D, Mannhardt I, Schulze T, Ulmer B, Werner T . Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat Protoc. 2017; 12(6):1177-1197. DOI: 10.1038/nprot.2017.033. View

17.

Barefield D, Kumar M, Gorham J, Seidman J, Seidman C, de Tombe P . Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. J Mol Cell Cardiol. 2014; 79:234-43. PMC: 4642280. DOI: 10.1016/j.yjmcc.2014.11.018. View

18.

Hayakawa T, Kunihiro T, Ando T, Kobayashi S, Matsui E, Yada H . Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol. 2014; 77:178-91. DOI: 10.1016/j.yjmcc.2014.09.010. View

19.

Frey N, Luedde M, Katus H . Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol. 2011; 9(2):91-100. DOI: 10.1038/nrcardio.2011.159. View

20.

Matsa E, Burridge P, Yu K, Ahrens J, Termglinchan V, Wu H . Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. Cell Stem Cell. 2016; 19(3):311-25. PMC: 5087997. DOI: 10.1016/j.stem.2016.07.006. View